Lilly agrees to acquire AtaiBeckley for up to $9.25 per share

Lilly agreed to acquire AtaiBeckley, a psychedelic-medicine developer, for $6.75 per share in cash plus a contingent value right worth up to $2.50 per share. The total potential consideration is up to $9.25 per share. The companies expect the deal to close in the third quarter of 2026.

• $6.75 per share in cash
• CVR worth up to $2.50 per share
• Total potential consideration up to $9.25 per share
• Expected close in Q3 2026